SpikImm

Executive Summary

SpikImm is a private French biotech company headquartered in Paris, focused on developing antibody-based biologics to address severe unmet medical needs. Its lead asset, SPK004, targets BK virus (BKV) reactivation in kidney transplant recipients, a critical complication arising from immunosuppressive therapy required to prevent graft rejection. BKV reactivation can lead to nephropathy and graft loss, with no approved therapies currently available. SpikImm's approach aims to provide a novel therapeutic option to improve outcomes for this vulnerable patient population. Founded in 2017, the company is in early stages with no disclosed funding, valuation, or pipeline details beyond SPK004. Given the high unmet need and the potential for first-in-class therapy, SpikImm represents a high-risk, high-reward opportunity contingent on successful clinical development and financing.

Upcoming Catalysts (preview)

• Q1 2026Phase 1/2 clinical trial initiation for SPK00440% success
• Q2 2026Series A funding round announcement50% success
• Q4 2025Preclinical data publication or presentation at major conference60% success